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isotope a prime candidate for several personalized nuclear 
medicine applications. 
This isotope can be produced in large quantities as a low 
specific activity (up to 800 GBq/g) product in reactors via the 
Sn-116(n,γ) or Sn-117(n,n’γ) reactions.  A carrier-free, high 
specific activity (up to 800 TBq/g) isotope can be 
manufactured with ~50 MeV cyclotrons employing either 
Sb(p,x) or Cd-116(α,3n).  Methods for extracting and 
purifying the Sn-117m from Sb or Cd have been developed.   
Sn-117m has been used to label a wide variety of targets 
including proteins, anti-bodies and small molecules.  In 
recent animal and human Phase I/II cardiovascular trials to 
detect and treat vulnerable plaque, the Sn-117m was 
chelated to aminobenzyl DOTA before being conjugated to 
annexin V.  Results demonstrated the ability of this molecule 
to both target and image the plaques.  Additionally, a 
remarkable therapeutic effect was observed at very low 
doses (~10 cGy). 
In oncology, Sn-117m (chelated to DTPA) has been 
successfully used in over 120 humans for bone pain palliation 
in a Phase I/II trial.  Labeling of neuroendocrine cancer 
targeting molecules has also been demonstrated.  The 
isotope, in low specific activity form, has been electroplated 
onto stents and implanted into several animal models to 
demonstrate the efficacy and finite range of the conversion 
electrons.  Human and veterinary applications are under 
development. 
Rheumatological applications include a homogeneous Sn-
117m colloid that is being used to treat (radiosynoviorthesis) 
canine osteoarthritis (OA).  Future veterinary applications 
include treating equine OA and human rheumatoid arthritis 
(RA).  Labeled compounds are also being developed to image 
and treat RA systemically. 
Additional future applications being explored take advantage 
of the limited irradiation of normal tissue in immune and 
inflammatory CNS conditions that could provide new 
therapeutic advantages to this immunologically privileged 
system.  In conclusion, the novel isotope Sn-117m is 
successfully finding application in several aspects of human 
nuclear medicine and is now also creating new opportunities 
in the emerging field of veterinary nuclear medicine. 
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Purpose: We have taken a comprehensive approach to 
develop biomarkers of potential therapeutic radioresponse. 
This approach includes gene, miRNA, and protein expression, 
as well as methylation and mutation analysis. Methods: 
Specimens from 102 HNSCC patients identified by surgical 
and pathologic criteria considered high risk for local 
recurrence (LR) or distant metastasis (DM) after post-
operative radiotherapy as well as 22 specimens from 
adjacent normal tissue were used. We have strived to avoid 
the pitfalls of biomarker discovery such as inadequate clinical 
phenotyping, the use of specimens of convenience, poorly 
annotated specimens, heterogeneous specimens and 
underpowered sample sets amongst others.  
Results: While a 46 gene signature was able to stratify 
patients based upon risk for overall survival, no gene 
signature was able to segregate specimens specific to LR or 
DM. This 46 gene signature, however, was able to stratify 
patients by overall survival in this data set, 5 independent 
HNSCC data sets as well as the TCGA data set. However, 
using a 36 miRNA signature PORT outcomes (LR or DM could 
be predicted. Unfortunately, when applied to the TCGA data 
set 13 miRNA were unavailable limiting the external 
validation to survival only. DNA methylation analysis, which is 
still ongoing, has identified DM and LR and includes genes in 
pathways associated with EMT and DNA repair, respectively. 
We have also taken the approach that biomarkers should 
have a biological basis and we have examined a set of 49 
HNSCC cells lines for gene and miRNA expression, and 
methylation. Furthermore, full radiation survival curves were 
generated. Filtering through miRNA target databases and 
examining negative correlations of miRNA and gene 
expression led to the isolation of several miRNA for further 
analysis. For example, miR-125a was under-represented in 
the LR cohort. miR-125a is a negative prognostic indicator in 
gastric cancer, targeting ERBB2. ERBB2 gene expression is 
anti-correlated with miR-125a expression in tumor specimens 
and in our 49 HNSCC cell lines. Furthermore, up-regulation of 
miR-125a in HN5 cells led to radiosensitization while down-
regulation of miR-125a led to radioresistance. Within the DM 
group, miR-551a and 551b-3p are over-represented. These 
miRNA drive cell proliferation, migration and invasion. A 
target of these miRNA is GLIPR2. The GLIPR2 protein binds 
BCLN1 and sequesters it within the golgi. Release of BCLN1 
allows cells to enter into autophagy and by modulating miRs 
551a and 551b-3p, we can drive cells into autophagy, 
enhance invasiveness and increase radioresistance.  
Conclusions: The expression of miRs 551a and 551b-3p as well 
as GLIPR2 gene expression can stratify patient outcome in 
our patient cohort, other HNSCC cohorts as well as other 
invasive cancers. Their expression is also highly associated 
with late stage HNSCC. Lastly, we are now integrating data 
sets to take a panomics approach to biomarker development. 
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Purpose: PET (”Positron Emission Tomography”) scanners 
have to guarantee high performances in term of spatial 
resolution and sensitivity allowing to detect cancer mass 
while it is still sufficiently small and has not had time to 
spread to other parts of the body. in this frame we focused 
on the development of the scintillator module that can reach 
high performance as compared to the current scanners and at 
the same time that keeps low costs and not complex design. 
To guarantee high performance in term of spatial resolution, 
the Depth of Interaction (DOI) information has to be reached. 
Instead of using the usual approach, with a double side 
readout, to have DOI capability we have developed a new 
PET module that can provide the DOI information using just a 
single side readout. 
Materials and Method: The module presented is based on a 64 
LYSO (“Lutetium-yttrium oxyorthosilicate”) crystals matrix 
and on an MPPC (“Multi Pixels Photon Counter”) as detector 
that guarantee a 4 to 1 coupling between the crystals and the 
detector and a single side readout. The lateral surfaces of 
the crystals are optically processed. Different configuration 
with light guide between the MPPC and the crystals matrix 
The readout of the signal is performed by a digitizer that 
record for each trigger event the charge collected by each 
MPPC after the integration of the signal. The digitizer is 
connected to a custom designed acquisition card that 
provides at the same time bias voltage to all the MPPC 
channels. The matrix is fixed to the board using a PVC 
custom made holder that also keep all the parts of the 
module in place. To characterize the module a 22Na 
radioactive source is placed 2 cm above the matrix exciting 
the scintillators. To test the DOI capability of the module a 
LYSO crystal is placed on the opposite side of the source 
allowing to illuminate a given vertical portion of the crystals 
and to permit to scan the vertical length of the module. 
Results: Combinations of the collected charge can be used to 
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identify in which crystal the scintillation event takes place 
but also can provide information about the depth of 
interaction of the gamma along the vertical length of the 
crystal. In the module the light output of the crystals is 
related to the vertical position of the interaction point and it 
is proved that the DOI can be reach using a single side 
readout. The different configurations are tested and 
compared to obtain the best DOI resolution.  
Conclusions: A innovative PET module is developed and 
tested and shows high performances according with a spatial 
resolution less then 1.5 mm and a DOI resolution of about 4 
mm FWHM obtained using a single side readout. 
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Microbeam Radiation Therapy (MRT) is a novel, promising 
technique for X-ray therapy [1]. The proposed treatment 
consists of intense, highly collimated, parallel arrays of X-ray 
beams of widths between 20 and 100 μm and separations 
between 100 and 400 μm generated by synchrotron radiation 
and suitable microslit collimators. Due to extremely high 
dose rate (up to 20 kGy/sec), a fast and reliable monitoring 
system is essential, but extremely challenging to construct, 
as it must cope with the high intensity, as well as very steep 
intensity gradients within the microscopic dimensions of the 
beams.  
In order to meet the requirements, the 3DMiMic collaboration 
has designed and fabricated 10 μm thick silicon strip beam 
monitors. Several strip layouts have been produced for 
simultaneous monitoring of the full array of microbeams.   
Tests using both single channel and multichannel readout  at 
the ESRF biomedical beam-line ID17 demonstrate that the 
detector and readout system work well and constitutes a 
viable system for coping with the challenge [2].  
In this presentation we will give details of the sensor design 
and results obtained from the tests at the ID17 beam-line. 2D 
response scans and time evolution studies of the sensor 
performed with an X-ray microprobe at the ID21 beam-line 
will also be presented.  
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Purpose: The highly localized dose distribution in proton 
therapy (PT) makes this treatment modality sensitive to 
organ motion and deformations. E.g. in proton pencil beam 
scanning interplay effects may be significant, resulting in 
dose degradations. Due to the complexity of PT dose 
delivery, investigations of the consequences of motion and of 
motion mitigation strategies may benefit from use of 3D 
dosimetry. A new family of silicone-based 3D dosimeters is 
currently being developed. These dosimeters can be moulded 
into anthropomorphic shapes and can be deformed during 
beam delivery, which allows for simulation of organ motion 
and deformation.  
Treatment planning with protons is based on CT scans of the 
patient anatomy and a conversion of the HU for the tissue to 
a stopping power ratio (SPR) relative to water. To ensure 
that the same procedure can be performed for the dosimeter 
it must be verified that its SPR is estimated correctly from its 
HU. The aim of this study was therefore to investigate if the 
use of Dual Energy (DE) CT and dedicated DE calibrations can 
improve the calculation of the SPR for the dosimeter 
compared to use of Single Energy (SE) CT together with the 
stoichiometric calibration method. 
Method: The dosimeter was CT scanned with a Dual Source 
CT scanner (Siemens Somaton Definition Flash). First a CT 
scan was obtained in SE mode with a tube voltage of 120 kVp, 
and this scan was used in the stoichiometric calibration. Next 
a set of CT scans was obtained in DE mode with a tube 
voltage pair of 80/140Sn kVp (Sn: 0.4 mm extra tin 
filtration); this CT image set was used for SPR calculation 
with two published DE calibrations. The CTDIvol of the two 
scanning modes was set to be the same (~20 mGy). 
A thin slab of the dosimeter material was placed in a water 
tank and irradiated with a 60 MeV proton beam. The range of 
the protons was measured with and without the dosimeter 
intersecting the beam to determine the range difference. 
The SPR of the dosimeter was calculated from its thickness 
and the range difference.  
Results: The two DE calibration methods both gave an 
estimate of SPRest = 1.01, whereas the SE stoichiometric 
calibration estimate was SPRest = 1.10. From the range 
measurements, the SPR of the dosimeter was calculated to 
be SPRmeas = 0.97. The measured SPR did not fall on the 
stoichiometric calibration curve of the reference tissues 
(Figure; the high content of silicon makes the dosimeter not 
tissue equivalent). The dosimeter was found to have a HU 
corresponding to bone (CT number = 135 HU) but a SPR 
corresponding to fat.  
 
